INSIGHTS

PierianDx Announces Multi-Year Agreement with Illumina to Support Cancer Research and Diagnostics

“Today, few laboratories have the ability to offer comprehensive tumor profiling because of the complexities associated with validating large NGS assays and interpreting genomic results. This agreement between PierianDx and Illumina has the potential to provide laboratories clinically optimized solutions that may accelerate assay validation and deployment and simplify genomic interpretation,” stated Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman, PierianDx. 

For Regular Updates:

Leave a comment

Your email address will not be published. Required fields are marked *